| P2093 | author name string | Gaurav Gupta | |
| | Karl L Womer | |
| P2860 | cites work | Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule | Q34298838 |
| | Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance | Q34448410 |
| | Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. | Q34464636 |
| | Strategies to improve long-term outcomes after renal transplantation | Q34539775 |
| | Five-year safety and efficacy of belatacept in renal transplantation | Q34621558 |
| | The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation | Q34922215 |
| | Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells | Q36368842 |
| | Why hasn't eliminating acute rejection improved graft survival? | Q36604328 |
| | Drug insight: maintenance immunosuppression in kidney transplant recipients | Q36662474 |
| | Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. | Q37256978 |
| | What's next in the pipeline | Q37283960 |
| | Costimulatory pathways in transplantation: challenges and new developments. | Q37474958 |
| | The pathogenesis and treatment of chronic allograft nephropathy | Q37563986 |
| | Novel immunosuppressive agents in kidney transplantation. | Q37737381 |
| | Belatacept in clinical and experimental transplantation - progress and promise | Q39869624 |
| | Abatacept binds to the Fc receptor CD64 but does not mediate complement-dependent cytotoxicity or antibody-dependent cellular cytotoxicity | Q40084849 |
| | Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. | Q40459668 |
| | Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids | Q43102233 |
| | A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). | Q44247085 |
| | The natural history of chronic allograft nephropathy | Q44688416 |
| | Cutting Edge: CD28 Controls Peripheral Homeostasis of CD4+CD25+ Regulatory T Cells | Q46025217 |
| | Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy | Q46177054 |
| | Prevention of calcineurin inhibitor nephrotoxicity in renal transplantation | Q46346481 |
| | Costimulation blockade with belatacept in renal transplantation | Q46569880 |
| | Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways | Q46963324 |
| | Cardiovascular complications after renal transplantation and their prevention. | Q50788889 |
| | Patient survival after renal transplantation; more than 25 years follow-up. | Q50939199 |
| | Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. | Q51541351 |
| | Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. | Q51758531 |
| | Late onset Pneumocystis pneumonia in renal transplantation after long-term immunosuppression with belatacept. | Q51826948 |
| | The OPTN/UNOS Renal Transplant Registry. | Q51917732 |
| | Belatacept and basiliximab diminish human antiporcine xenoreactivity and synergize to inhibit alloimmunity | Q56900861 |
| | Sirolimus Versus Cyclosporine in Kidney Recipients Receiving Thymoglobulin®, Mycophenolate Mofetil and a 6-Month Course of Steroids | Q56908156 |
| | Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors | Q56909582 |
| | Renal transplantation | Q72442105 |
| | Induction of allograft tolerance through costimulatory blockade: first selection of drugs in vitro | Q73508405 |
| | Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates | Q74365181 |
| | Combination induction therapy with monoclonal antibodies specific for CD80, CD86, and CD154 in nonhuman primate renal transplantation | Q78571274 |
| | Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig | Q79290408 |
| | Engraftment of adult porcine islet xenografts in diabetic nonhuman primates through targeting of costimulation pathways | Q81227024 |
| | A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study) | Q84102539 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunosuppressive drug | Q249619 |
| | globulins | Q321710 |
| | blood proteins | Q425056 |
| | kidney transplantation | Q740909 |
| P304 | page(s) | 375-382 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Drug Design, Development and Therapy | Q2566724 |
| P1476 | title | Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation | |
| P478 | volume | 4 | |